AstraZeneca plc vs Bank of Montreal — how do they compare? AstraZeneca plc trades at $158.15 (market cap $248.14B), while Bank of Montreal trades at $182.04 (market cap $126.83B). The key difference: AstraZeneca plc is the larger of the two by market cap, and Bank of Montreal pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| AZN | BMO | |
|---|---|---|
Market Cap | $248.14B | $126.83B |
Sector | Health | Financials |
52-Week High | $209.48 | $183.65 |
52-Week Low | $147.06 | $112.54 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | 2.69% |
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →